Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, Farid Hashemi, Ebrahim Rahmani Moghadam, Mehdi Raei, Mahshad Kalantari, Shima Tavakol, Reza Mohammadinejad, Masoud Najafi, Franklin R. Tay, Pooyan Makvandi

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.

Original languageEnglish (US)
Pages (from-to)669-700
Number of pages32
JournalACS Combinatorial Science
Volume22
Issue number12
DOIs
StatePublished - Dec 14 2020

Keywords

  • anticancer therapy
  • chemotherapy
  • co-delivery platforms
  • nanocarriers
  • natural products
  • small interfering RNA

ASJC Scopus subject areas

  • Chemistry(all)

Fingerprint

Dive into the research topics of 'Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy'. Together they form a unique fingerprint.

Cite this